Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Rhea-AI Summary
Edesa Biotech (Nasdaq: EDSA) reported fiscal third quarter 2026 results and business updates for the periods ended June 30, 2026. The company completed preparations for its Phase 2 EB06 vitiligo trial during the quarter and, after quarter-end, began activating initial investigational sites, with patient recruitment expected to start in the coming weeks in Canada, subject to regulatory and administrative approvals.
In its respiratory program, additional exploratory analyses in ARDS patients with concurrent acute kidney injury showed paridiprubart plus standard of care was associated with significant mortality reductions and improvements in the kidney-specific MAKE30 endpoint. Operating expenses rose to $5.5 million in Q3 and $12.2 million year-to-date, driving net losses of $5.4 million (Q3) and $11.9 million (nine months). Edesa reported $10.3 million in cash and cash equivalents and working capital of $6.9 million at June 30, 2026.
Positive
- EB06 Phase 2 vitiligo trial preparations completed; site activation underway
- Paridiprubart ARDS+AKI analyses showed mortality reductions and improved MAKE30 endpoint
- Q3 cash and cash equivalents of $10.3 million
- Nine-month net cash provided by financing of $6.8 million
Negative
- Q3 operating expenses increased to $5.5 million from $1.9 million
- Q3 net loss widened to $5.4 million from $1.7 million
- Nine-month net loss rose to $11.9 million from $5.0 million
- Government reimbursement funding decreased, reducing other income by $0.2 million year-to-date
- Current liabilities increased to $3.9 million and shareholders’ equity declined
News Explained
As of
Sources and calculations
- Edesa Biotech Fiscal 3rd Quarter 2026 Results (2026-08-13)
- Edesa Biotech latest supplied quarterly fundamentals (2026Q2)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $10,000,000 / ($2,016,622 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Private placement | Negative | +8.4% | Private placement financing drew a positive response despite dilution-related transaction characteristics. |
| Jun 05 | Clinical data | Positive | -23.0% | Exploratory AKI data reported lower mortality and MAKE30 incidence with paridiprubart. |
| May 19 | Clinical presentation | Positive | +32.8% | Company announced an oral presentation of exploratory paridiprubart AKI data. |
| May 14 | Q2 earnings | Negative | -10.7% | Quarterly results showed higher operating expenses, wider losses, and reduced working capital. |
| Mar 31 | Clinical presentation | Positive | +6.1% | Company scheduled presentations of Phase 3 paridiprubart ARDS data at ATS events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: one positive clinical-data event diverged negatively, while the fiscal Q2 report aligned negatively.
Key Terms
monoclonal antibody medical
ards medical
aki medical
make30 composite endpoint medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.
During the third quarter, Edesa completed preparations for its Phase 2 clinical study of EB06 (an anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo. Subsequent to quarter-end, the company began activating its first investigational sites and expects recruitment to begin in the coming weeks in Canada, with additional jurisdictions to follow, subject to regulatory approval and administrative filings. In its respiratory program, the company conducted additional exploratory analyses to evaluate paridiprubart’s effect in ARDS patients with concurrent acute kidney injury (AKI). In this population, paridiprubart plus standard of care treatment was associated with significant mortality reductions supported by concordant improvements in the kidney-specific MAKE30 composite endpoint. Edesa continues to evaluate potential regulatory pathways in major markets while advancing strategic discussions for the program.
"Our third quarter marked an important operational inflection point for Edesa, with the completion of preparations for our Phase 2 vitiligo study keeping us on track for initial enrollment in the coming weeks," said Par Nijhawan, MD, Chief Executive Officer of Edesa. "In addition, the positive exploratory data in patients with acute kidney injury further reinforce the versatility of paridiprubart and support our engagement with potential partners as we advance late-stage development and evaluate future commercialization pathways."
Edesa’s Chief Financial Officer Peter Weiler said third quarter results tracked to the company’s operating plan, with spending beginning to shift from preparatory activities toward clinical trial execution. “We are prioritizing execution of the EB06 Phase 2 study while continuing to support regulatory, manufacturing and business development activities for paridiprubart,” he said.
Financial Results for the Three Months Ended June 30, 2026
Total operating expenses increased by
- Research and development expenses increased by
$3.1 million to$4.0 million for the three months ended June 30, 2026 compared to$0.9 million for the same period last year primarily due to increased expenses for manufacturing-related activities and other preparations for the planned Phase 2 clinical study of EB06 in vitiligo patients, as well as increased unallocated research costs, which were partially offset by decreased expenditures for the company’s paridiprubart program.
- General and administrative expenses increased by
$0.6 million to$1.6 million for the three months ended June 30, 2026 compared to$1.0 million for the same period last year primarily due to increases in noncash share-based compensation and professional fees.
Total other income decreased by approximately
For the quarter ended June 30, 2026, Edesa reported a net loss of
Financial Results for the Nine Months Ended June 30, 2026
Total operating expenses increased by
- Research and development expenses increased by
$5.4 million to$7.8 million for the nine months ended June 30, 2026 compared to$2.4 million for the same period last year primarily due to increased expenses for manufacturing-related activities and other preparations for the planned Phase 2 clinical study of EB06 in vitiligo patients, as well as increased unallocated research costs, which were partially offset by decreased expenditures for the company’s paridiprubart program.
- General and administrative expenses increased by
$1.3 million to$4.3 million for the nine months ended June 30, 2026 compared to$3.0 million for the same period last year primarily due to increases in noncash share-based compensation and professional fees.
Total other income decreased by
For the nine months ended June 30, 2026, Edesa reported a net loss of
Working Capital
At June 30, 2026, Edesa had cash and cash equivalents of
Calendar
Edesa management is scheduled to participate in the H.C. Wainwright 28th Annual Global Investment Conference to be held September 12-13, 2026 in New York, NY. Attendees interested in meeting with company representatives can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: the company's plans and expectations regarding the conduct of its Phase 2 clinical study of EB06 in vitiligo patients; the company's expectation that patient recruitment and enrollment will commence in the coming weeks in Canada, with additional jurisdictions to follow, subject to regulatory approvals and any required administrative filings; the company's belief that findings from its exploratory analyses in ARDS patients with acute kidney injury at baseline further support the therapeutic potential of paridiprubart; the company's plans to evaluate potential regulatory pathways for paridiprubart in major markets; the company's plans to engage in strategic and business development discussions regarding paridiprubart, including with potential partners, and the potential outcomes of such discussions; the company's plans to advance paridiprubart through late-stage development and evaluate future commercialization opportunities; the company's belief that the third quarter represented an important operational milestone for the company; the company's expectations regarding the shift in spending from preparatory activities toward clinical trial execution and the composition of its operating expenses; the company's plans regarding capital allocation, including prioritizing execution of the Phase 2 EB06 study while continuing to support regulatory and business development activities for paridiprubart; and the company's timing and plans regarding its clinical programs in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
| Condensed Interim Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||||
| Expenses: | ||||||||||||||||
| Research and development | 3,957,875 | 939,067 | $ | 7,849,690 | $ | 2,443,191 | ||||||||||
| General and administrative | 1,561,674 | 964,676 | 4,308,236 | 2,998,127 | ||||||||||||
| Loss from operations | (5,519,549 | ) | (1,903,743 | ) | (12,157,926 | ) | (5,441,318 | ) | ||||||||
| Other Income (Loss): | ||||||||||||||||
| Reimbursement grant income | 107,368 | 183,281 | 276,021 | 536,744 | ||||||||||||
| Other income (loss) | 111,938 | 154,279 | 285,114 | 484,953 | ||||||||||||
| Loss before income taxes | (5,407,611 | ) | (1,749,464 | ) | (11,872,812 | ) | (4,956,365 | ) | ||||||||
| Income tax expense | - | - | 800 | 800 | ||||||||||||
| Net loss | (5,407,611 | ) | (1,749,464 | ) | (11,873,612 | ) | (4,957,165 | ) | ||||||||
| Exchange differences on translation | 27,548 | 164,611 | 7,230 | 119,536 | ||||||||||||
| Net comprehensive loss | $ | (5,380,063 | ) | $ | (1,584,853 | ) | $ | (11,866,382 | ) | $ | (4,837,629 | ) | ||||
| Weighted average number of common shares | 9,007,474 | 7,022,678 | 8,504,968 | 5,217,343 | ||||||||||||
| Loss per common share - basic and diluted | $ | (0.60 | ) | $ | (0.25 | ) | $ | (1.40 | ) | $ | (0.95 | ) | ||||
| Condensed Interim Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| June 30, 2026 | September 30, 2025 | |||||||
| Assets: | ||||||||
| Cash and cash equivalents | $ | 10,332,520 | $ | 10,792,172 | ||||
| Other current assets | 447,758 | 720,704 | ||||||
| Non-current assets | 1,940,917 | 2,017,642 | ||||||
| Total Assets | $ | 12,721,195 | $ | 13,530,518 | ||||
| Liabilities and shareholders' equity: | ||||||||
| Current liabilities | $ | 3,910,041 | $ | 1,078,536 | ||||
| Shareholders' equity | 8,811,154 | 12,451,982 | ||||||
| Total liabilities and shareholders' equity | $ | 12,721,195 | $ | 13,530,518 | ||||
| Condensed Interim Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended | ||||||||
| June 30, 2026 | June 30, 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (11,873,612 | ) | $ | (4,957,165 | ) | ||
| Adjustments for non-cash items | 1,509,154 | 418,622 | ||||||
| Change in working capital items | 3,177,829 | (1,062,725 | ) | |||||
| Net cash used in operating activities | (7,186,629 | ) | (5,601,268 | ) | ||||
| Net cash provided by financing activities | 6,793,376 | 16,844,415 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | (66,399 | ) | 81,223 | |||||
| Net change in cash and cash equivalents | (459,652 | ) | 11,324,370 | |||||
| Cash and cash equivalents, beginning of period | 10,792,172 | 1,037,320 | ||||||
| Cash and cash equivalents, end of period | $ | 10,332,520 | $ | 12,361,690 | ||||
